Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B

Table 1 Baseline demographics (n = 163) n (%)

Age (yr)
Mean age	52.0 (24-86)
Mean age at start	47.4 (20-81)
Gender
Males	113 (69.3)
Females	50 (30.7)
Pre-treatment Biopsies	134 (82.2)
Duration of therapy (mo)
Range	3-46
Mean	25.63
Median	23
Patients > 24 mo	79 (48.5)
Patients > 36 mo	49 (30.1)
Co-infection
Hepatitis C	1 (0.61)
HBV DNA load (IU/mL)
> 100  000	95 (58.3)
2000-100  000	45 (27.6)
12-2000	23 (14.1)
HBe antigen status	41 (25.2)
e antigen positive	112 (68.7)
e antigen negative	10 (6.1)
Unknown
ALT (U/L)
10-40	39 (23.9)
40-400	118 (72.4)
> 400	5 (3.01)
Unknown	1 (0.61)
Fibrosis score	0-10 (6.13)
135 (82.82%)	1-61 (37. 4)
	2-38 (23.3)
	3-17 (10.4)
	4-9 (5.52)
	Unknown-27 (16.6)

HBV: Hepatitis B virus; ALT: Alanine aminotransferase.